On Monday, Nifty continued with its upmove for the second consecutive session while the market participants were hoping that the bulls would win a hat-trick of gains; however, SGX Nifty is indicating a rough start on Tuesday amid darkening hopes of a fiscal relief package in the US before November 3 US Presidential elections.

The immediate resistance for Nifty is placed at the levels of 11,900 and a move above this could lead to the further upside towards 11,940, followed by the 12,000 mark.

Equitas Small Finance Bank is hitting the primary capital market with its IPO. Read on to find out if you should subscribe to the issue.

A money market fund is a type of debt fund that is supposed to have Macaulay duration of not more than one year. Read on to find out more.

Multi Commodity Exchange of India launched futures trading on the country’s first tradable real-time Base Metals Index, i.e. METLDEX.

The stock has given a downward sloping trendline breakout on the daily timeframe formed by connecting swing highs from June 2020. This breakout is confirmed by the above 50-day average volume.

On Monday, bulls dominated over the domestic markets as Sensex surged by 448.62 points or 1.12 per cent to settle at 40,431.60 levels while Nifty gained by 0.94 per cent or 110.60 points to close at 11,873.05 levels.

Zydus Cadila today announced that it has received tentative approval from USFDA to market Tofacitinib extended-release tablets, 11 mg (US RLD: Xeljanz XR® tablets).

Edelweiss Alternative Asset Advisors today announced the final close of its Rs 6,600 crore alternative investment fund - ESOF III.

Sirolimus tablets, 0.5 mg, 1 mg, and 2 mg are the generic version of Rapamune tablets, 0.5 mg, 1 mg, and 2 mg, of PF Prism CV. These tablets are used to prevent the rejection of kidney transplants.